Amalia Mihai, market access manager of Ipsen Romania explains that over the course of 26 years Ipsen has been increasingly helping Romanian patients in the field of oncology, neurodegenerative disorders, gastroenterology and endocrinology. She reveals that a successful market launch entails having a patient-centric approach, supporting patients not only with products, but also new devices that educate and enhance adherence to treatment. She highlights through the launch of innovative medicines, such as cabozantinib – a new targeted therapy in oncology - the challenges of access in the Romanian market, such as the pricing methodology, and delayed reimbursement for patients.
Increasingly, medicines are putting pressure on public funds, that is why companies must contribute to facilitating patient access to treatment in accordance with the applicable legislation
